<DOC>
	<DOCNO>NCT01011309</DOCNO>
	<brief_summary>The purpose study determine efficacy , safety , immunogenicity investigational vaccine develop treatment leishmaniasis , include cutaneous leishmaniasis ( CL ) . The vaccine , identify LEISH-F2 + MPL-SE , consist Leishmania protein ( LEISH-F2 ) together adjuvant MPL-SE .</brief_summary>
	<brief_title>A Study Efficacy Safety LEISH-F2 + MPL-SE Vaccine Treatment Cutaneous Leishmaniasis</brief_title>
	<detailed_description>A phase 2 , randomize , open-label , control study evaluate efficacy , safety , immunogenicity vaccine administer three time ( 10 μg LEISH-F2 + 25 μg MPL-SE Days 0 , 28 56 ) treatment adults adolescent CL compare treatment standard chemotherapy ( 20 mg/kg/day sodium stibogluconate 20 day ) . The proportion cure group determine use clinical criterion .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antimony Sodium Gluconate</mesh_term>
	<criteria>Males female ≥ 12 year &lt; 70 year age . In first stage study , patient age ≥ 18 year &lt; 70 year enrol . In second stage , enrollment also include adolescent patient age ≥ 12 &lt; 18 year . Must clinical diagnosis cutaneous leishmaniasis confirm positive identification Leishmania parasite identification L. peruviana PCR . Lesions must clear superinfection prior enrollment . Female patient childbearing age must negative serum pregnancy test screening , negative urine pregnancy test within 24 hour first vaccination initiation chemotherapy , must breastfeed , require use adequate contraception Day 84 study . These precaution necessary due unknown effect LEISHF2 + MPL SE , sodium stibogluconate might fetus newborn infant . The following laboratory blood test must value within normal range screen : sodium , potassium , urea , total bilirubin , ALT , AST , glucose , creatinine , alkaline phosphatase , total WBC count platelet count . Hemoglobin may exceed ULN since patient reside Andes high altitude ( 20 g/dL ) The following serology test must negative screening : HIV1/2 , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . All patient ( parent ) receive HIVrelated counsel prior testing . Patients positive HIV test result refer counsel treatment appropriate . Potential study patient ( guardian ) must give write informed consent , willing house Lima minimum 20 day 63 day , able attend require followup visit , permanent address , reachable study site personnel . Infection species L.peruviana confirm PCR . Presence eleven active cutaneous leishmaniasis lesion . The diameter ulcerated area single lesion &gt; 60 mm . Presence lesion superinfection time enrollment . History mucocutaneous leishmaniasis diagnosis mucocutaneous leishmaniasis screening . History previous exposure Leishmania vaccine . Known use injected oral corticosteroid within 6 week prior first vaccination initiation chemotherapy . Participation another experimental protocol receipt investigational product within 30 day prior first vaccination initiation chemotherapy . History autoimmune disease cause immunosuppressive state . History evidence acute chronic illness , opinion study clinician , may interfere evaluation safety immunogenicity vaccine . ( Patients present concomitant illness refer standard clinical care ) . History use medication , opinion study clinician , may interfere evaluation safety immunogenicity vaccine . History significant psychiatric illness . Drug addiction include alcohol abuse . Patients history previous anaphylaxis , severe allergic reaction vaccine unknown allergen , allergic reaction egg . Patients unlikely cooperate requirement study protocol . ECG evidence ventricular arrythmias ≥ 4 extra systole per minute . Known allergy contraindication chemotherapy ( e.g. , know reaction pentavalent antimonials , cardiopathy , myocarditis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
</DOC>